JP2021508318A5 - - Google Patents

Download PDF

Info

Publication number
JP2021508318A5
JP2021508318A5 JP2020531663A JP2020531663A JP2021508318A5 JP 2021508318 A5 JP2021508318 A5 JP 2021508318A5 JP 2020531663 A JP2020531663 A JP 2020531663A JP 2020531663 A JP2020531663 A JP 2020531663A JP 2021508318 A5 JP2021508318 A5 JP 2021508318A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
heteroaryl
heterocycloalkyl
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020531663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508318A (ja
JP7319977B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/064114 external-priority patent/WO2019113242A1/en
Publication of JP2021508318A publication Critical patent/JP2021508318A/ja
Publication of JP2021508318A5 publication Critical patent/JP2021508318A5/ja
Application granted granted Critical
Publication of JP7319977B2 publication Critical patent/JP7319977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020531663A 2017-12-06 2018-12-05 チューブリン阻害剤 Active JP7319977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595530P 2017-12-06 2017-12-06
US62/595,530 2017-12-06
PCT/US2018/064114 WO2019113242A1 (en) 2017-12-06 2018-12-05 Tubulin inhibitors

Publications (3)

Publication Number Publication Date
JP2021508318A JP2021508318A (ja) 2021-03-04
JP2021508318A5 true JP2021508318A5 (enExample) 2022-01-11
JP7319977B2 JP7319977B2 (ja) 2023-08-02

Family

ID=66658388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020531663A Active JP7319977B2 (ja) 2017-12-06 2018-12-05 チューブリン阻害剤

Country Status (8)

Country Link
US (3) US11040945B2 (enExample)
EP (1) EP3720436A4 (enExample)
JP (1) JP7319977B2 (enExample)
KR (1) KR20200104873A (enExample)
CN (1) CN111727042A (enExample)
AU (1) AU2018380132B2 (enExample)
TW (1) TWI828644B (enExample)
WO (1) WO2019113242A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
CN111741944B (zh) * 2018-02-01 2025-01-03 悉尼大学 抗癌化合物
CA3122371A1 (en) 2018-12-07 2020-06-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
PH12022550029A1 (en) 2019-07-31 2023-02-27 Aclaris Therapeutics Inc Deuterated mk2 pathway inhibitors and methods of using the same
US20210147441A1 (en) * 2019-09-26 2021-05-20 Agency For Science, Technology And Research (A*Star) Therapeutic compounds and methods of use thereof
EP4076448A4 (en) 2019-12-20 2024-03-27 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
CN115484952B (zh) 2020-03-27 2024-10-18 阿克拉瑞斯治疗股份有限公司 被取代的吡啶酮-吡啶基化合物的方法、组合物和结晶形式
WO2022103149A1 (ko) * 2020-11-10 2022-05-19 주식회사 큐라클 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
IL306101A (en) * 2021-03-23 2023-11-01 Gen1E Lifesciences Inc Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors
EP4333841A1 (en) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2205732A1 (de) 1972-02-08 1973-08-16 Thomae Gmbh Dr K Neue 4-(4-biphenylyl)-butensaeurederivate
IT1044222B (it) * 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
AT336594B (de) 1973-08-14 1977-05-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer 3-(4- biphenylyl)-buttersaureamiden
US5196543A (en) 1989-10-17 1993-03-23 Delalande S.A. 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
WO1991019730A1 (en) 1990-06-14 1991-12-26 Monsanto Company Rna hydrolysis/cleavage
JP2969618B2 (ja) * 1995-06-27 1999-11-02 田辺製薬株式会社 ピリダジノン誘導体及びその製法
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP3060454B2 (ja) * 1996-12-26 2000-07-10 田辺製薬株式会社 医薬組成物
GEP20053476B (en) 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2004294354B2 (en) 2003-12-03 2009-02-19 Ym Biosciences Australia Pty Ltd Tubulin inhibitors
BRPI0511295A (pt) 2004-05-18 2007-12-04 Schering Corp 2-quinolil-oxazóis substituìdos úteis como inibidores de pde4
CN101052398A (zh) 2004-10-29 2007-10-10 默克公司 作为雄激素受体调节剂的n-(吡啶-3-基)-2-苯基丁酰胺
CA2599538C (en) * 2005-03-15 2013-07-30 Nycomed Gmbh N-sulphonylpyrroles and their use as histone deacetylase inhibitors
WO2007123953A2 (en) 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
JP2009185010A (ja) 2008-02-08 2009-08-20 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤を含有する医薬
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BR112012003661A2 (pt) * 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
SG183192A1 (en) * 2010-03-10 2012-09-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
US20130267712A1 (en) 2012-04-02 2013-10-10 Board Of Trustees Of Northern Illinois University Aromatic ketone synthesis with amide reagents and related reactions
US20160039827A1 (en) 2013-03-15 2016-02-11 Nanyang Technological University Activation of carbonyl beta-carbons for chemical transformations
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
WO2016067009A1 (en) 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
BR112017016333A2 (pt) * 2015-01-30 2018-04-03 Univ Sydney compostos anticâncer
EP3302448B1 (en) 2015-06-04 2023-10-25 Aurigene Oncology Limited Substituted heterocyclyl derivatives as cdk inhibitors

Similar Documents

Publication Publication Date Title
JP2021508318A5 (enExample)
JP2019518766A5 (enExample)
JP2019524883A5 (enExample)
JP2019031560A5 (enExample)
JP2017537940A5 (enExample)
JP2020510091A5 (enExample)
JP2016513130A5 (enExample)
JP2017512833A5 (enExample)
JP2014501766A5 (enExample)
JP2018529650A5 (enExample)
JP2015537020A5 (enExample)
JP2017511357A5 (enExample)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2015508092A5 (enExample)
JP2014521688A5 (enExample)
JP2017071634A5 (enExample)
JP2018519343A5 (enExample)
JP2016121196A5 (enExample)
JP2017508816A5 (enExample)
JP2017528502A5 (enExample)
JP2012513416A5 (enExample)
JP2015521195A5 (enExample)
JP2018529739A5 (enExample)
JP2016503797A5 (enExample)
JP2017509586A5 (enExample)